Calprotectin in infections and sepsis, Version 1.0 20200728
Research type
Research Study
Full title
An observational study to evaluate the diagnostic and predictive accuracy of Calprotectin in patients with severe infections and sepsis
IRAS ID
266594
Contact name
David Brealey
Contact email
Sponsor organisation
Gentian AS
Duration of Study in the UK
1 years, 7 months, 16 days
Research summary
The rapidly growing problem with antibiotic resistance has resulted in demands for more specific and restrictive use of antibiotics. Biomarkers with ability to diagnose an infection in early stage and distinguish between bacterial and viral infection could possibly reduce overuse of antibiotics.
Furthermore, early diagnosis of infections and sepsis may help clinicians to select patients with risk to develop severe infections and sepsis, to use antibiotics more selectively and minimize the risk of the development of severe complications and death.
Calprotectin is manly expressed in neutrophils and is released from activated neutrophils in an early stage of immune response to pathogens.
This study aims to investigate potential of calprotectin to predict and diagnose severe infections and sepsis.REC name
London - Queen Square Research Ethics Committee
REC reference
20/LO/1024
Date of REC Opinion
30 Sep 2020
REC opinion
Favourable Opinion